Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer

Experimental and Therapeutic Medicine

Volumn 5, Issue 5, 2013, Pages 1506-1510

  Jiang, Hong ^a   Yu, Xin Ming ^b   Zhou, Xing Ming ^a   Wang, Xiao Hong ^b   Su, Dan ^b  

^a Treatment Technology Research   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

tubulin III; Chemotherapy; Lung tumor; Stathmin

Indexed keywords

BETA TUBULIN; CISPLATIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MESSENGER RNA; NAVELBINE; PHYCOERYTHRIN; STATHMIN;

ADENOCARCINOMA; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CHEMOSENSITIVITY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; GENE EXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MICROTUBULE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATHOLOGY; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 84876580519     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1007     Document Type: Article

References (21)

1. Volz A, Weiss E, Trowsdale J and Ziegler A: Presence of an expressed beta-tubulin gene (TUBB) in the HLA class I region may provide the genetic basis for HLA-linked microtubule dysfunction. Hum Genet 93: 42-6, 1994.
2. Séve P and Dumontet C: Class III beta tubulin expression in non-small cell lung cancer. Rev Mal Respir 27: 383-386, 2010 (In French).
3. Jeon TY, Han ME, Lee YW, et al: Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 102: 710-718, 2010.
4. Gan L, Guo K, Li Y, et al: Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncol Rep 23: 1037-1043, 2010.
5. Yuan SF, Chen WJ, Zhu LJ, et al: Effects of monoclonal antibodies against human stathmin combined with paclitaxel on proliferation of the QG-56 human lung carcinoma cell line. Asian Pac J Cancer Prev 13: 2967-2971, 2012.
6. Eastham LL, Mills CN and Niles RM: PPARalpha/gamma expression and activity in mouse and human melanocytes and melanoma cells. Pharm Res 25: 1327-1333, 2008.
7. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ER-CC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
8. Bepler G, Kusmartseva I, Sharma S, et al: RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24: 4731-4737, 2006.
9. Papadaki C, Tsaroucha E, Kaklamanis L, et al: Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer 104: 316-323, 2011.
10. Papadaki C, Sfakianaki M, Ioannidis G, et al: ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol 7: 663-671, 2012.
11. Reynolds C, Obasaju C, Schell MJ, et al: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27: 5808-5815, 2009.
12. Mariani M, Shahabi S, Sieber S, Scambia G and Ferlini C: Class III β-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med 11: 726-731, 2011.
13. Koh Y, Jang B, Han SW, et al: Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 5: 320-325, 2010.
14. Séve P, Lai R, Reiman T, et al: Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small-cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13: 994-999, 2007.
15. Séve P, Isaac S, Trédan O, et al: Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11: 5481-5486, 2005.
16. Reiman T, Lai R, Veillard AS, et al: Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol 23: 86-93, 2012.
17. Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ and Purohit A: Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 102: 316-324, 2010.
18. Hansch C and Verma RP: Understanding tubulin/microtubule-taxane interactions: a quantitative structure-activity relationship study. Mol Pharm 5: 151-161, 2008.
19. Singer S, Malz M, Herpel E, et al: Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 69: 2234-2243, 2009.
20. Pu X, Wang J, Xu L, et al: Relationship between expression of beta-tubulin-III plus stathmin in advanced non-small cell lung cancer and its sensitivity to venorelbine chemotherapy. Zhongguo Fei Ai Za Zhi 12: 49-53, 2009 (In Chinese).
21. Singer S, Malz M, Herpel E, et al: Coordinated expression of stathmin family members by far upstream sequence element binding protein-1 increases motility in non-small cell lung cancer. J Cancer Res 69: 2234-2243, 2009.